<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82332">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01948648</url>
  </required_header>
  <id_info>
    <org_study_id>B2013:075</org_study_id>
    <nct_id>NCT01948648</nct_id>
  </id_info>
  <brief_title>Effects of Colesevelam</brief_title>
  <official_title>Effects of Colesevelam as an Adjunct Therapy for Sitosterolemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <authority>Canada: Ethics Review Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      If treatment of colesevelam in conjunction with ezetimibe, will lead to further reduction in
      plasma plant sterol levels in sitosterolemia patients. We hypothesize that treatment with
      colesevelam decrease cholesterol absorption and increase cholesterol fractional synthesis in
      sitosterolemia patients. This hypothesis will be examined by measuring changes in
      cholesterol absorption and synthesis using isotope technique.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Plasma plant sterol level</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>plasma plant sterol assessment using Gas Chromatography(GC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cholesterol absorption</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>use of stable isotope technique to assess cholesterol absorption</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cholesterol synthesis</measure>
    <time_frame>16 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>use of stable isotope to assess cholesterol synthesis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Sitosterolemia</condition>
  <arm_group>
    <arm_group_label>Colesevelam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3.75mg/day for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3.75 mg/day for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Colesevelam</intervention_name>
    <arm_group_label>Colesevelam</arm_group_label>
    <other_name>Lodalis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>placebo</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar Pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed diagnosis of homozygous sitosterolemia as established by genotyping  and/or
             clinical parameters

          2. Receiving ezetimibe treatment

          3. Over 12 years of age (no maximum)

          4. Concomitant illnesses or conditions

        Exclusion Criteria:

          1. Pregnancy

          2. Intellectual disability

          3. Bowel or biliary obstruction

          4. Known hypersensitivity to colesevelam or any ingredients of colesevelam
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Richardson Center for Functional Foods and Nutraceuticals</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 25, 2013</lastchanged_date>
  <firstreceived_date>September 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>plant sterols</keyword>
  <keyword>cholesterol</keyword>
  <keyword>colesevelam</keyword>
  <keyword>phytosterolemia</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Lipid Metabolism, Inborn Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colesevelam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
